Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Eiger BioPharmaceuticals, Inc. (EIGR)
Last eiger biopharmaceuticals, inc. earnings: 3/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.eigerbio.com
Company Research
Source: PR Newswire
PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy™ (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL). Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8809251-eiger-biopharmaceuticals-fda-approval-zokinvy-progeria/ Progeria and Progeroid Laminopathies are separate and distinct ultra-rare, genetic, premature aging diseases that accelerate mortality in young patients. Disease manifestations include growth failure, loss of body fat and hair, aged-looking skin, stiffness of joints, hip dislocation, generalized atherosclerosis, cardiovascular disease and stroke. Untreated children with Progeria die of hear
Show less
Read more
Impact Snapshot
Event Time:
EIGR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EIGR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EIGR alerts
High impacting Eiger BioPharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EIGR
News
- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- BRNS, UPC and KWE among mid-day movers [Seeking Alpha]Seeking Alpha
- Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection [Yahoo! Finance]Yahoo! Finance
- Eiger BioPharmaceuticals Files for Voluntary Chapter 11 ProtectionGlobeNewswire
- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
EIGR
Sec Filings
- 4/25/24 - Form 25-NSE
- 4/8/24 - Form 10-K
- 4/3/24 - Form 8-K
- EIGR's page on the SEC website